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Edited by Ned ManteiAbstract To assess the potential for functional interaction
between synectin and neurotrophin receptors (Trk receptors) in
the nervous system, we characterized synectin expression in the
rat brain. Synectin is widely expressed in the brain and its
expression levels are regulated both temporally and spatially,
correlating with those of Trk receptors. Biochemical studies
indicated that synectin interacts with TrkB but not with TrkC in
the developing brain. We also found that axotomized motoneu-
rons upregulate synectin mRNA expression as well as TrkB
mRNA. These data suggest that synectin plays a role in neural
development and regeneration in association with TrkB.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Synectin (also designated GIPC, SEMCAP-1 or GLUT1-
CBP) is a PDZ protein that contains a central PDZ domain
and a C-terminal acyl carrier domain, and has been identiﬁed
as an interaction partner of syndecan-4, RGS-GAIP, SemaF,
and glucose 1 transporter [1–4]. Synectin is widely expressed in
mammalian tissues, including the brain [1–4]. Electron mi-
croscopic studies have deﬁned the localization of synectin on
clathrin-coated vesicles, suggesting a role of synectin in the
process of endocytosis [2,5]. However, intracellular functions
of synectin are still poorly understood.
Synectin has been reported to have the ability to interact
with neurotrophin receptors, which are receptor tyrosine ki-
nases (Trk receptors) [6]. Neurotrophins, including nerve
growth factor (NGF), brain-derived neurotrophic factor
(BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/
5), act to promote the growth, diﬀerentiation, and survival of
neurons in the peripheral nervous system (PNS) and central
nervous system (CNS) [7]. In addition, recent studies have
shown a role of neurotrophins in synapse development and
plasticity [8]. Neurotrophins exert their functions by interact-
ing with diﬀerent subsets of Trk receptors: NGF binds to
TrkA, BDNF and NT4 to TrkB, and NT3 to TrkC. Interac-
tion of neurotrophins with Trk receptors triggers multiple
signal pathways and initiates internalization of the ligand–* Corresponding author. Fax: +81-53-435-2290.
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complex is critical for some biological functions of neurotro-
phins [9,10]. The molecular mechanisms governing the process
of internalization are not well understood. However, clathrin-
dependent endocytosis is likely involved in this process [10,11].
It is therefore conceivable that synectin may associate with
internalized ligand–Trk complex in clathrin-coated vesicles.
To better understand the functional relevance of interactions
between Trk receptors and synectin, we characterize here sy-
nectin expression in developing and mature rat brain and study
the interaction between synectin and Trk receptors in the CNS.
Furthermore, to investigate functional relevance of Trk re-
ceptors and synectin in the PNS, we use an animal model with
facial nerve injury, which is known to cause upregulation of
BDNF and TrkB [12], and examine gene regulation of synectin
mRNA in this model.2. Materials and methods
2.1. Animals
For the developmental study, Wistar male rats of postnatal day one,
three, seven, 14, 21 and 28 days, and 8 week (n ¼ 3 at each time point)
were used. For the regeneration study, male Wistar rats (150 g) were
subjected to the operation described in the next section.
2.2. Motor nerve transection
The left facial nerve was transected under pentobarbital anesthesia.
The facial nerve was transected at a point just distal to the posterior
auricular branch and about 5 mm of the distal nerve segment was
removed. Following a postoperative time of 1, 3, 7, 14, 21 or 28 days,
the animals (n ¼ 5 to 6 at each time point) were subjected to analysis
by in situ hybridization histochemistry.
2.3. Immunohistochemistry
Wistar male rats (200 g) were deeply anesthetized and intracardially
perfusedwith 4%paraformaldehyde in PBS. Brainswere postﬁxed in the
same ﬁxative overnight and cryoprotected in 30% sucrose in PBS. Fro-
zen sections (18 lm thick) were cut on a cryostat, blocked 3 h at room
temperature in PBS containing 0.3% Triton-X, 1% goat serum, and 1%
albumin, and then incubated in the following solutions at 4 C: anti-
synectin antibody (1:1000) in blocking solution for 2 days, 0.1MPBS for
30 min, biotinylated goat anti-rabbit antiserum (1:500, Vector Labora-
tories) in blocking buﬀer overnight, washed in PBS for 30 min, VEC-
TASTAIN ABC reagent (Vector Laboratories) for 1 h, and ﬁnally
visualizedwith diaminobenzidine (DAB) as a substrate.Control sections
that underwent the same procedure except for the incubation with anti-
synectin antibody did not show any immunoreactivity (data not shown).
2.4. In situ hybridization histochemistry
Animals were deeply anesthetized with diethylether and sacriﬁced.
The brains were immediately removed, embedded in OCT, and quicklyblished by Elsevier B.V. All rights reserved.
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on a cryostat and kept at )20 C until use. The synectin mRNA-spe-
ciﬁc oligonucleotide probe, corresponding to nucleotide positions 86–
125 of the rat synectin cDNA (Accession No. AF089817), was labeled
with [35S]dATP using terminal deoxynucleotidyl transferase. Sub-
sequent procedures were described in detail elsewhere [13]. To compare
the data for diﬀerent animals at each time point, hybridization for all
animals was done at the same time and with the same probe. The
sections were exposed to BIOMAX MR ﬁlm (Kodak) for 7 days and
thereafter dipped in NBT2 nuclear track emulsion (Kodak) followed
by exposure in a dark box for three weeks. Some slides were then
stained with Thionine. In competition experiments in which sections
were hybridized with a 300-fold excess of a non-labeled probe, hy-
bridization signals were virtually absent. For quantitative analysis of
the results, we counted silver grains located on typical ﬁve facial
motoneurons in the control and operated sides and performed statis-
tical analysis.
2.5. Immunoblotting, subcellular fractionation and
coimmunoprecipitation
Brain samples were homogenized in lysis buﬀer [50 mM Tris, pH 7.4,
150 mM NaCl, 1 mM DTT, 1.5 mM MgCl2, 4 mM EDTA, 10% (v/v)
glycerol and complete protease inhibitor cocktail (Roche Diagnostics),
containing 1% (v/v) Triton X-100] using a Teﬂon Potter-Elvehjem
homogenizer. Homogenates were kept on ice for 60 min and cleared by
centrifugation at 15 000 rpm for 30 min. The supernatant was collected
and its protein concentration was measured by the Bradford method.
The sample was separated by SDS–PAGE and transferred to a ni-
trocellulose membrane (Schleicher & Sch€uell). The membrane was
blocked with 5% (w/v) non-fat dried milk powder in PBS for 60 min
followed by a 12 h incubation with primary antibodies. After washing,
bound Igs were visualized with horseradish peroxidase-conjugated
secondary antibodies using the ECL system (Pierce).
Subcellular fractionations of rat brains were prepared as described
by Li et al. [14]. In brief, whole brains were homogenized in 4 mM
HEPES, pH 7.4, containing 0.32 M sucrose and proteinase inhibitors,
using a Teﬂon Potter-Elvehjem homogenizer. Homogenates wereFig. 1. Synectin expression in the adult CNS. (A) Western blot analysis sh
respective protein extracts from brain was loaded per lane. The anti-synectin
fractionations of the adult rat brain were performed as described in Section
cytoplasmic soluble fraction (S3). In the synaptosomal fraction, synectin is e
but barely detectable in the synaptic vesicle fraction (LP2). (C) Immunohisto
was observed in the pyramidal cells of cerebral cortex (a), hippocampal pyram
olfactory bulb (d). Scale bar ¼ 50 lm (a, c, d), 400 lm (b). Abbreviations: DG
granule cell layer; Mi, mitral cell layer; Pj, Purkinje cell.centrifuged at 800· g for 10 min to yield pellet P1. The supernatant
was collected and centrifuged at 9200· g for 15 min, yielding a pellet
(P2) and supernatant (S2). The S2 fraction was further centrifuged at
165 000· g for 60 min. The resulting supernatant represents the soluble
fraction (S3). The P2 pellet was resuspended in homogenization buﬀer
and represents a crude synaptosome fraction. The crude synaptosome
fraction was lysed by adding 10 vol. of ice-cold water containing
protease inhibitors followed by homogenization with a glass-Teﬂon
homogenizer. The synaptic membrane fraction (LP1) was collected
from this homogenate by centrifugation at 25 000· g for 20 min, and
the supernatant was further centrifuged at 165 000· g for 60 min to
give crude synaptic vesicle pellet (LP2) and supernatant (LS2) frac-
tions. For coimmunoprecipitation, LP1 and LP2 fractions were col-
lected from the brain of a P14 rat and homogenized in TNE buﬀer [10
mM Tris, pH 8.0, 150 mM NaCl, 1mM EDTA, 1% NP-40 and com-
plete protease inhibitor cocktail (Roche Diagnostics)]. The homogen-
ates were cleared by centrifugation at 15 000 rpm for 30 min and the
supernatant was incubated for 1 h at 4 C with anti-Trk antibody or
non-immunized rabbit whole IgG fraction (control) followed by in-
cubation with protein A–Sepharose (Amersham) for an additional 1 h
at 4 C. The beads were washed extensively with TNE buﬀer and
proteins retained on the beads were eluted with SDS–PAGE sample
buﬀer. Anti-Trk antibody (C-14) that recognizes full-length TrkA,
TrkB, and TrkC was purchased from Santa Cruz Biotechnology. Anti-
synectin antibody was kindly provided by Prof. M. Simons [1].
2.6. Yeast two-hybrid analyses
The DupLexA yeast two-hybrid system (Origene) was used for in-
teraction analyses. The cDNA fragment encoding the juxtamembrane
region of TrkB (residues 458–543) or TrkC (residues 459–545) was
ampliﬁed by polymerase chain reaction from a rat brain cDNA library
(Origene). The products were subcloned in frame into the inducible
pGilda bait plasmid to generate pGilda-TrkB and pGilda-TrkC, and
veriﬁed by DNA sequencing. The pJG4-5 prey plasmid including a
cDNA fragment encoding synectin (residues 119–333) or PSD-95
(residues 33–724) was obtained by yeast two-hybrid screening which
we performed previously [15].owing a wide-spread expression of synectin in the CNS. 30 lg of the
antibody recognized a band corresponding to 40 kDa. (B) Subcellular
2. 8 lg of protein was loaded in each lane. Synectin is abundant in the
nriched in the high-speed supernatant of synaptosomal fraction (LS2)
chemical localization of synectin. Strong immunoreactivity for synectin
idal cells (b), Purkinje cells in the cerebellum (c), and mitral cells in the
, dentate gyrus; Epl, external plexiform layer; Gl, glomerular layer; Gr,
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3.1. Regional distribution of synectin protein in the adult brain
Several studies have documented the wide tissue distribution
of synectin mRNA and protein, with highest levels of expres-
sion being found in the brain, lung, and heart [1–4]. To de-
termine the regional distribution of synectin in the adult rat
CNS, 1% Triton-X soluble proteins were collected from the
olfactory bulb, caudate putamen, cerebral cortex, thalamus,
hippocampus, midbrain, and cerebellum, and subjected to
Western blot analysis (Fig. 1A). On Western blots, anti-
synectin antibody reacted with a ca. 40 kDa protein that
corresponds to the apparent molecular mass of synectin de-
termined in previous studies [1,3,4,6]. As indicated in Fig. 1A,
synectin was widely expressed in the adult brain and we did not
ﬁnd signiﬁcant diﬀerences in the levels of synectin expression
among brain regions.
To characterize the subcellular localization of synectin, we
fractionated homogenates of adult brain according to a stan-
dard procedure (Section 2.5) [14,16] and analyzed the fractions
with the same antibody (Fig. 1B). Synectin was abundant in the
soluble S3 fraction and the high-speed supernatant (LS2), and in
the crude synaptosomal fraction (P2), suggesting the presence of
large cytosolic pools of synectin in the brain. In the P2 fraction
(9200 g pellet), synectin was also present in the membrane
fractions, but primarily associated with synaptic membranes
(LP1) and barely detected in the small vesicle fraction (LP2).
To better deﬁne the cells that contain synectin in the brain,
we performed immunohistochemistry (Fig. 1C). On tissue sec-
tions from the adult rat brain, synectin immunoreactivity was
observed in neuron populations throughout the brain. Strong
immunoreactivity for synectin was detected in the cytoplasm of
neurons and this was in agreement with the data showing the
abundance of synectin in the soluble S3 fraction. The most
prominent expression was observed in the mitral cells of ol-
factory bulb (Fig. 1C-d), pyramidal neurons of cerebral cortex
(Fig. 1C-a), pyramidal cells in the hippocampus (Fig. 1C-b),
Purkinje cells in the cerebellum (Fig. 1C-c), and neurons in the
cerebellar nuclei (data not shown). Dendrites of cerebral py-
ramidal neurons and Purkinje cells were clearly labeled.
3.2. Developmental expression of synectin in the rat brain
To examine developmental changes in synectin expression,
total brain homogenates of several developmental stages wereFig. 2. Synectin expression during postnatal CNS development. Wes-
tern blot analysis showing relative protein levels for synectin in the
developing brain. 30 lg of total brain extract was separated on 7.5%
SDS–PAGE and blotted on a nitrocellulose membrane. Lanes corre-
spond to postnatal days (P1, P3, P7, P14, and adulthood).analyzed by Western blotting (Fig. 2). Synectin expression was
low in the neonatal brain, but markedly increased during the
ﬁrst three days. High levels of synectin expression were ob-
served at P3, P7, and P14. Thereafter, synectin expression
decreased and moderate levels of expression were observed in
adulthood. Subsequent in situ hybridization histochemistry
conﬁrmed and extended these ﬁndings. Synectin mRNA was
ubiquitously expressed in the brain, while expression levels
were signiﬁcantly changed postnatally (Fig. 3). At P0, synectin
mRNA expression was very weak in all brain regions exam-
ined, which contrasted to intense signals in the olfactoryFig. 3. Synectin mRNA expression in the postnatal CNS. (A–D)
Horizontal brain sections at P0 (A), P7 (B), P14 (C), and in adult (D)
showing in situ hybridization signals for synectin mRNA. Scale bar¼ 1
mm. (E,F) Bright-ﬁeld micrographs showing accumulation of hybrid-
ization signals on the mitral cells (mit) in the olfactory bulb (E) and
pyramidal cells (py) in the hippocampus (F). Scale bar ¼ 50 lm.
Abbreviations: Am, Ammon’s horn of hippocampus; CC, corpus
callosum; Ceb, cerebellum; CPu, caudate putamen; Cx, cerebral cortex;
Gr, granule cell layer of olfactory bulb; gr, granule cell; Hip, hippo-
campus; MB, midbrain; Mit, mitral cell layer of olfactory bulb; ol-
factory bulb; OE, olfactory epithelia; Th, thalamus.
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nectin expression was dramatically upregulated with regional
diﬀerences in the signal intensity. At P7, high signal levels were
detected in the hippocampus and olfactory bulb. In particular,
Ammon’s horn of the hippocampus (Am) and the mitral cell
layer (Mit) of the olfactory bulb were intensely labeled with the
probe. Moderate signal levels were detected in the granule cell
layer (Gr) of olfactory bulb, cerebral cortex (Cx), and thala-
mus (Th) (Fig. 3B). Signal levels reached their postnatal
maximum at P14. At this time, signiﬁcant levels of synectin
mRNA expression were also observed in the caudate putamen
(CPu) (Fig. 3C). Hybridization signals were distributed over
the neuronal population throughout the brain (Fig. 3E and F),
in good agreement with the immunohistochemistry analysis.
Thereafter, synectin mRNA expression was reduced in most
brain regions. In the adult brain, intense signals remained only
in the Ammon’s horn of the hippocampus (Fig. 3D). Syna-
ptogenesis takes place extensively in the ﬁrst few weeks after
birth [17], and adult synaptic plasticity has been well studied in
the cerebral cortex and hippocampus [18]. Thus, expression
patterns of synectin in the developing and matured brains
suggest that synectin might be involved in synapse develop-
ment and synaptic plasticity.
3.3. In vivo association of Trk and synectin
We are interested in the fact that synectin has the ability to
interact with neurotrophin receptors, TrkA and TrkB [6].
However, it is still unclear whether Trk receptors interact with
synectin in the CNS. To consider this, we ﬁrst asked whether
these two molecules are present in the relevant locations. The
expression of Trk receptors in the CNS has been studied [19].
In contrast to the very restricted localization of TrkA, TrkB
and TrkC are widely distributed in the adult CNS. In partic-
ular, TrkB and TrkC are highly expressed in the hippocampus,
cerebellum, and cerebral cortex. In addition, expression ofFig. 4. Biochemical interaction between synectin and Trk. (A) Yeast two-hyb
and PSD-95. Positive interactions were determined by b-galactosidase assay
TrkB and synectin show an interaction. (B) Subcellular localizations of Trk
each lane. Note that signiﬁcant levels of synectin were recovered in the LP2 f
LP1 and LP2 fractions were prepared from P14 rat brain, incubated with an
precipitated with protein A–Sepharose. Proteins retained on the beads were
synectin Ab. Synectin and Trk were coprecipitated with anti-Trk Ab (lane 3),
immunoreactivity in the input sample.TrkB and TrkC mRNA is developmentally regulated, and
transiently exhibits peak levels during the ﬁrst two postnatal
weeks [20]. Spatio-temporal expression patterns for TrkB and
TrkC were thus seemingly correlated and synchronized with
those of synectin (Fig. 3).
Lou et al. [6] have demonstrated that synectin (GIPC) is a
binding partner of TrkA and TrkB, and have shown that the
synectin binding site is located in the juxtamembrane region of
these Trk receptors. However, it has not yet been determined
whether TrkC also has the ability to interact with synectin. To
test this, we generated bait constructs encoding a juxtamem-
brane region of TrkB or TrkC, and performed yeast two-
hybrid analyses (Fig. 4A). As expected, we could detect the
interaction between TrkB and synectin. However, despite
structural homology in the juxtamembrane region between
TrkB and TrkC, no interaction was found between TrkC and
synectin. Synectin has a central PDZ domain through which it
binds to TrkB [6]. To further investigate the speciﬁcity of
binding between synectin’s PDZ domain and TrkB, we also
tested the binding ability of TrkB to PSD-95, which involves
three PDZ domains within the PSD-95 structure. As shown in
Fig. 4A, no interaction could be detected between TrkB and
PSD-95, suggesting that the interaction between TrkB and
synectin’s PDZ domain is highly speciﬁc.
In the adult brain, we detected only a small amount of sy-
nectin in the LP2 fraction, where small vesicles in the synapse
are primarily recovered [16]. We speculated that if synectin
associates with internalized ligand–Trk complex in clathrin-
coated vesicles, synectin and Trk receptors should be enriched
in the LP2 fraction of the developing brain. In fact, we found
that synectin is present mainly as a membrane-associated form
(LP1 and LP2) in the developing synapses (Fig. 4B), in con-
trast to the adult brain where lesser amounts of synectin are
found in these fractions (Fig. 1B). To examine in vivo inter-
action between synectin and Trk receptors, coimmunoprecip-rid analyses of Trk receptor (TrkB and TrkC) interaction with synectin
and cell growth on the selection plates (–Ura, –Trp, –His, –Leu). Only
receptors and synectin in P14 rat brain. 10 lg of protein was loaded in
raction. (C) Coimmunoprecipitation of synectin by anti-Trk antibody.
ti-Trk Ab or non-immunized whole rabbit IgG fraction (control) and
eluted, separated on 10% SDS–PAGE and immunoblotted with anti-
but not with non-immunized rabbit IgG (lane 2). Lane 1 shows synectin
H. Kato et al. / FEBS Letters 572 (2004) 123–128 127itation was carried out on LP1 and LP2 fractions of P14 rat
brain. Anti-Trk antibody precipitated synectin (Fig. 4C), while
non-immunized rabbit whole IgG fraction did not, supporting
the idea that synectin interacts with Trk receptors in vivo.
Taken together, our results suggest that synectin interacts with
TrkB in the clathrin-coated vesicles and that this interaction
may be necessary for BDNF signaling and functions in syn-
apse development and plasticity.
3.4. Upregulation of synectin mRNA following motor nerve
transection
Kobayashi et al. [12] have documented that BDNF and
TrkB are upregulated by facial nerve transection. Given that
synectin is functionally associated with TrkB in the PNS, sy-
nectin mRNA may also be upregulated after motor nerve
transection. Based on this hypothesis, we examined gene reg-
ulation of synectin mRNA following motor nerve transection
(Fig. 5). After nerve transection, synectin mRNA was
promptly upregulated in the facial nucleus on the operated sideFig. 5. Upregulation of synectin mRNA expression in facial motoneurons fo
changes in synectin mRNA expression in facial nucleus at postoperative day 1
of synectin mRNA expression in the facial nucleus on the operated side (rig
bar¼ 500 lm. (B) Bright-ﬁeld micrographs showing the localization of enhan
bar ¼ 50 lm. (C) Changes in the levels of hybridization signals after nerve
counted on each side and the ratio of counts between an axotomized and a c
Each data point represents the mean values from ﬁve trials using diﬀerent nand enhanced hybridization signals were already observed at
postoperative day 1 (Fig. 5A). Expression levels of synectin
mRNA were increased during the ﬁrst postoperative week and
reached a maximum around postoperative day 7, with about 4-
fold greater hybridization signals compared to the control side.
In the second postoperative week, synectin mRNA expression
began to decline and returned to the control level at postop-
erative day 28. Nerve transection did not aﬀect the levels of
synectin mRNA expression in the facial nucleus on the con-
tralateral side. Enhanced signals for synectin mRNA were
exclusively accumulated on the facial motoneurons (Fig. 5B).
Fig. 5C summarizes the changes in expression levels of synectin
mRNA after facial nerve transection. To verify that the up-
regulation of synectin gene expression is also induced in an-
other peripheral motor system, we performed the same
examination using a model of masseteric nerve transection,
and found that synectin mRNA was also upregulated in the
axotomized trigeminal motoneurons (data not shown). These
results indicated that upregulation of synectin gene is possiblyllowing facial nerve transection. (A) Dark-ﬁeld micrographs showing
, 3, 7, 14, 21, and 28. Nerve transection induced transient enhancement
ht), but did not aﬀect expression levels on the control side (left). Scale
ced hybridization signals on the axotomized facial motoneurons. Scale
transection. The number of silver grains on a facial motoneuron was
ontrol facial motoneuron was calculated as relative amount of signal.
eurons±S.E.M.
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synectin may play an important role in the process of nerve
regeneration. In facial motoneurons, trkB mRNA starts to
increase 2 days after axotomy and persists for 2–3 weeks [12].
The time-course of synectin mRNA expression after axotomy
was largely synchronized with gene regulation of trkB mRNA
expression in the axotomized motoneurons, which support the
notion that synectin may functionally associate with TrkB in
the PNS.
The Ras–Raf–Erk pathway is critical to regenerative
growth of peripheral nerves [21]. In fact, previous studies have
documented that Erk1/2 are activated in the axotomized
motoneurons [22,23], although it has not yet been deﬁned
how Erk1/2 is activated. Interestingly, overexpression of
synectin (GIPC) in PC12 cells selectively decreases NGF-
induced Erk1/2 activation with no eﬀect on Shc, Akt, or PLC-
c1 [6]. This suggests that increased synectin expression after
axotomy may reﬂect a need for synectin in the activation of
Erk1/2. Interaction of neurotrophins with Trk receptors ini-
tiates clathrin-dependent internalization of the ligand-receptor
complexes, which is critical for some biological functions of
neurotrophins including neurite outgrowth in PC12 cells [10].
Indeed, Howe et al. (2001) have demonstrated that Erk1/2
activation occurs at clathrin-coated vesicles in NGF-treated
PC12 cells [11]. These ﬁndings are reminiscent of electron
microscopic observations showing the localization of synectin
in clathrin-coated vesicles [2,5] and also subcellular fractio-
nations shown in Fig. 4B. It has been suggested that BDNF
interacts with TrkB at the proximal stump of lesioned motor
nerves [12]. We speculate that internalized BDNF-TrkB as-
sociates with synectin in clathrin-coated vesicles and this as-
sociation may provide a platform to recruit additional
signaling components for the activation of Erk1/2. Alterna-
tively, synectin may be involved in the clathrin-mediated en-
docytosis machinery governing the internalization of the
BDNF-TrkB complexes.
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